Therefore, expression in blastemal-predominant tumours would be expected to be higher than in triphasic or epithelial-predominant or stromal (WT1-mutant) tumours where the aggregating blastemal cells would express lower levels of FOXD1. Here, FOXD1 is linked to neoplasm.